These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085 [TBL] [Abstract][Full Text] [Related]
10. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052 [TBL] [Abstract][Full Text] [Related]
11. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056 [TBL] [Abstract][Full Text] [Related]
12. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974 [TBL] [Abstract][Full Text] [Related]
13. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725 [TBL] [Abstract][Full Text] [Related]
14. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Schwäble J; Choudhary C; Thiede C; Tickenbrock L; Sargin B; Steur C; Rehage M; Rudat A; Brandts C; Berdel WE; Müller-Tidow C; Serve H Blood; 2005 Mar; 105(5):2107-14. PubMed ID: 15536149 [TBL] [Abstract][Full Text] [Related]
15. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Mizuki M; Schwable J; Steur C; Choudhary C; Agrawal S; Sargin B; Steffen B; Matsumura I; Kanakura Y; Böhmer FD; Müller-Tidow C; Berdel WE; Serve H Blood; 2003 Apr; 101(8):3164-73. PubMed ID: 12468433 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354 [TBL] [Abstract][Full Text] [Related]